Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome

Leukemia

Volumn 18, Issue 1, 2004, Pages 146-155

  Simonitsch Klupp, I ^a   Hauser, I ^b   Ott, G ^c   Drach, J ^a   Ackermann, J ^a   Kaufmann, J ^a   Weltermann, A ^b   Greinix, H T ^a   Skrabs, C ^b   Dittrich, C ^d   Lutz, D ^e   Potter R ^a   Mannhalter, C ^a   Lechner, K ^b   Chott, A ^a   Jaeger, Ulrich ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d KAISER FRANZ JOSEF HOSPITAL   (Austria)

^e Vienna General Hospital ^*  (Austria)

Author keywords

DLBCL; Outcome; Plasmablastic; TP53

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IMMUNOGLOBULIN HEAVY CHAIN; METHOTREXATE; PREDNISONE; PROTEIN BCL 6; PROTEIN P53; SYNDECAN 1; VINCRISTINE;

ADULT; AGED; ALLELE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLASTIC LYMPHOMA; IMMUNOGLOBULIN VARIABLE REGION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OBSERVER VARIATION; PHENOTYPE; PLASMACYTOMA; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 10744228902     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403206     Document Type: Review

References (40)

1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994; 84: 1361-1392.
2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airle House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
3. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001, pp 171-174.
4. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non Hodgkin's lymphoma. N Engl J Med 1993; 328: 987-1006.
5. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non Hodgkin's lymphoma. N Engl J Med 1998; 239: 21-26.
6. Armitage JO, Weisenburger DD. New approach to classifying non Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project. J Clin Oncol 1998; 16: 2780-2795.
7. Lennert K, Feller AC. Histopathology of non Hodgkin's lymphomas (based on the updated Kiel classification) with a section of clinical therapy. In: M Engelhard, G Brittinger (eds). Berlin: Springer-Verlag, 1992, 115-127.
8. Engelhard M, Brittinger G, Huhn D, Gerhartz HH, Meusers P, Siegert W et al. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood 1997; 89: 2291-2297.
9. Schlegelberger B, Zwingers T, Harder L, Nowotny H, Siebert R, Vesely M et al. Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Blood 1999; 94: 3114-3120.
10. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
11. Rosenwald A, Wright G, Chan WC, Connors J, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
12. Colomo L, López-Guillermo A, Perales M, Rives S, Martinez A, Bosch F et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84.
13. Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997; 89: 1413-1420.
14. Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000; 95: 1406-1412.
15. De Paepe P, Baens M, Van Krieken H, Verhasselt B, Stul M, Simons A et al. ALK activation by the CTLC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 2003; 102: 2638-2641.
16. Gascoyne RD, Lamant L, Martin-Subero JI, Valia S, Lestou VS, Harris NL et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of six cases. Blood 2003; 102: 2568-2573.
17. Onciu M, Behm FG, Downing JR, Shurtleff SA, Raimondi SC, Ma Z, Morris SW et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of two cases. Blood 2003; 102: 2642-2644.
18. Bonadonna G, Monfardini S. Chemotherapy on non-Hodgkin's lymphomas. Cancer Treat Rev 1974; 1: 167-181.
19. Longo DL, DeVita Jr VT, Duffey PL, Wesley MN, Ihde DC, Hubbard SM et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 1991; 9: 25-38.
20. Cahanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693-697.
21. Fridrik MA, Hausmaninger H, Linkesch W, Steger M, Sill H, Neubauer M et al. CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial. J Clin Oncol 1996; 14: 227-232.
22. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244.
23. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S et al. Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117-122.
24. Colwill R, Crump M, Couture F, Danish R, Stewart AK, Sutton DM et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995; 13: 396-402.
25. Apperley JF, Girinsky T, Friedrich WI. Conditioning regimens. In: Apperley JF, Gluckman E, Gratwohl A (eds). Blood and Marrow Transplantation. Paris: ESH, 1998, pp 98-115.
26. Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
27. Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34: 187-220.
28. Chott A, Haedicke W, Mosberger I, Fodinger M, Winkler K, Mannhalter C et al. Most CD56+ intestinal lymphomas are CD8+CD5- T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol 1998; 153: 1483-1490.
29. Drach J, Ackermann J, Fritz E, Kromer E, Schuster R, Gisslinger H et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998; 92: 802-809.
30. Welzel N, Le T, Marculescu R, Mitterbauer G, Chott A, Pott C et al. Templated nucleoticle addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res 2001; 61: 1629-1636.
31. Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 2084-2092.
32. Lossos IS, Jones CD, Warnke R, Natkunam Y, Kaizer H, Zehnder JL et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001; 98: 945-951.
33. Hsu FJ, Levy R. Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma. Blood 1995; 86: 3072-3082.
34. Lossos IS, Okada CY, Tibshirani R, Warnke R, Vose JM, Greiner TC et al. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. Blood 2000; 95: 1797-1803.
35. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997; 337: 529-534.
36. Offit K, Lo Coco F, Louie DC, Parsa NZ, Leung D, Portlock C et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 1994; 331: 74-80.
37. Filipits M, Stranzl T, Pohl G, Heinzl H, Jager U, Geissler K et al. Drug resistance factors in acute myeloid leukemia: a comparative analysis. Leukemia 2000; 14: 68-76.
38. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R et al CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
39. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA et al. Plasmablastic morphology - an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998; 91: 2501-2507.
40. Lamant L, Pulford K, Bischof D, Morris SW, Mason DY, Delsol G et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000; 156: 1711-1721.